1 ic effects of MET withdrawal with daily i.p. homocystine.

2                  In this assay, S-adenosyl-l-homocystine (AdoHcy/SAH), the by-product of PMT-involved

3 to its low molecular weight disulfide forms (homocystine and homocysteine-cysteine mixed disulfide) b

4 ulfide, cysteine, cystine, homocysteine, and homocystine and the therapeutic agents penicillamine, pe

5 d for homocysteine persulfide synthesis from homocystine by CSE only.

6 ysis confirmed the defect in SAA metabolism: homocystine, cysteine, cystathionine and serine were sig

7                     Only a small fraction of homocystine is formed by an oxidative process in which c

8 teine, because equimolar concentrations of L-homocystine, L-cysteine, and L-methionine had no effect

9                  The latter then reacts with homocystine or homocysteine-cysteine mixed disulfide to

10  internal standard, [3,3,3',3',4,4,4',4'-2H8]homocystine to account for losses associated with the is

11 ith homocysteine-cysteine mixed disulfide or homocystine to form albumin-bound homocysteine.